- Home
- VERV vs MTLS Comparison
VERV vs MTLS Comparison
Compare VERV & MTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERV
- MTLS
- Stock Information
- Founded
- VERV 2018
- MTLS 1990
- Country
- VERV United States
- MTLS Belgium
- Employees
- VERV N/A
- MTLS N/A
- Industry
- VERV Medicinal Chemicals and Botanical Products
- MTLS Computer Software: Prepackaged Software
- Sector
- VERV Health Care
- MTLS Technology
- Exchange
- VERV Nasdaq
- MTLS Nasdaq
- Market Cap
- VERV 382.5M
- MTLS 418.2M
- IPO Year
- VERV 2021
- MTLS 2014
- Fundamental
- Price
- VERV $4.79
- MTLS $6.89
- Analyst Decision
- VERV Strong Buy
- MTLS Buy
- Analyst Count
- VERV 4
- MTLS 1
- Target Price
- VERV $25.75
- MTLS $9.50
- AVG Volume (30 Days)
- VERV 1.4M
- MTLS 251.7K
- Earning Date
- VERV 11-05-2024
- MTLS 10-24-2024
- Dividend Yield
- VERV N/A
- MTLS N/A
- EPS Growth
- VERV N/A
- MTLS 323.01
- EPS
- VERV N/A
- MTLS 0.19
- Revenue
- VERV $24,396,000.00
- MTLS $297,100,156.00
- Revenue This Year
- VERV $84.66
- MTLS $7.93
- Revenue Next Year
- VERV N/A
- MTLS $10.21
- P/E Ratio
- VERV N/A
- MTLS $36.52
- Revenue Growth
- VERV 219.91
- MTLS 5.07
- 52 Week Low
- VERV $4.31
- MTLS $4.70
- 52 Week High
- VERV $19.34
- MTLS $7.56
- Technical
- Relative Strength Index (RSI)
- VERV 32.80
- MTLS 62.91
- Support Level
- VERV $6.02
- MTLS $6.02
- Resistance Level
- VERV $6.68
- MTLS $7.56
- Average True Range (ATR)
- VERV 0.47
- MTLS 0.34
- MACD
- VERV -0.14
- MTLS 0.08
- Stochastic Oscillator
- VERV 0.25
- MTLS 60.82
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
About MTLS Materialise NV
Materialise NV is a provider of 3D printing services. The products and services of the group are organized in three segments: Medical segment, which develops and delivers medical software solutions, medical devices, and other related products and services; Software segment, which develops and delivers additive manufacturing software solutions and related services; and Manufacturing segment, which delivers 3D printed products and related services. Its geographical segments are the United States, the Americas (excluding the USA), Belgium, Germany, Poland, France, Switzerland, the United Kingdom, Italy, the Netherlands, Other Europe, and the Asia Pacific.